A novel pathological role of p53 in kidney development revealed by gene-environment interactions

American Journal of Physiology - Renal Physiology

Volumn 288, Issue 1 57-1, 2005, Pages

  Fan, Hao ^a   Harrell, Jessica R ^a   Dipp, Susana ^a   Saifudeen, Zubaida ^a   El Dahr, Samir S ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Bradykinin B2 receptor; Checkpoint kinase; Histone acetylation; Knockout mice

Indexed keywords

BRADYKININ B3 RECEPTOR; HISTONE DEACETYLASE INHIBITOR; PROTEIN P53; UVOMORULIN;

ANIMAL MODEL; ARTICLE; CONGENITAL DISORDER; CONTROLLED STUDY; DEFENSE MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; GAMMA IRRADIATION; GENE INTERACTION; GENETIC SUSCEPTIBILITY; GENETIC TRANSFECTION; HUMAN; IMMUNOPRECIPITATION; KIDNEY DEVELOPMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGENY; REDUCTION;

EID: 11144267135     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00246.2004     Document Type: Article

References (57)

1. Ashcroft M, Kubbutat MH, and Vousden KH. Regulation of p53 function and stability by phosphorylation. Mol Cell Biol 19: 1751-1758, 1999.
2. Berger SL. Histone modifications in transcriptional regulation. Curr Opin Genet Dev 12: 142-148, 2002.
3. Bergin E, Levine JS, Koh JS, and Lieberthal W. Mouse proximal tubular cell-cell adhesion inhibits apoptosis by a cadherin-dependent mechanism. Am J Physiol Renal Physiol 278: F758-F768, 2000.
4. Birchmeier W and Behrens J. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta 1198: 11-26, 1994.
5. Borkowski JA, Ransom RW, Seabrook GR, Trumbauer M, Chen H, Hill RG, Strader CD, and Hess JF. Targeted disruption of a B2 bradykinin receptor gene in mice eliminates bradykinin action in smooth muscle and neurons. J Biol Chem 270: 13706-13710, 1995.
6. Boussadia O, Kutsch S, Hierholzer A, Delmas V, and Kemler R. E-cadherin is a survival factor for the lactating mouse mammary gland. Mech Dev 115: 53-62, 2002.
7. Bussemakers MJ, Giroldi LA, van Bokhoven A, and Schalken JA. Transcriptional regulation of the human E-cadherin gene in human prostate cancer cell lines: characterization of the human E-cadherin gene promoter. Biochem Biophys Res Commun 203: 1284-1290, 1994.
8. Cadwell C and Zambetti GP. Regulators and mediators of the p53 tumor suppressor. J Cell Biochem Suppl 30-31: 43-49, 1998.
9. 2 receptor null mice. Hypertension 34: 176-180, 1999.
10. Conacci-Sorrell M, Zhurinsky J, and Ben-Ze'ev A. The cadherin-catenin adhesion system in signaling and cancer. J Clin Invest 109: 987-991, 2002.
11. Cordenonsi M, Dupont S, Maretto S, Insinga A, Imbriano C, and Piccolo S. Links between tumor suppressors: p53 is required for TGF-γ gene responses by cooperating with Smads. Cell 113: 301-314, 2003.
12. Dahl U, Sjodin A, Larue L, Radice GL, Cajander S, Takeichi M, Kemler R, and Semb H. Genetic dissection of cadherin function during nephrogenesis. Mol Cell Biol 22: 1474-1487, 2002.
13. Damia G, Sanchez Y, Erba E, and Broggini M. DNA damage induces p53-dependent down-regulation of hCHK1. J Biol Chem 276: 10641-10645, 2001.
14. Day ML, Zhao X, Vallorosi CJ, Putzi M, Powell CT, Lin C, and Day KC. E-cadherin mediates aggregation-dependent survival of prostate and mammary epithelial cells through the retinoblastoma cell cycle control pathway. J Biol Chem 274: 9656-9664, 1999.
15. Dmitrieva NI, Cai Q, and Burg MB. Cells adapted to high NaCl have many DNA breaks and impaired DNA repair both in cell culture and in vivo. Proc Natl Acad Sci USA 101: 2317-2322, 2004.
16. El-Dahr SS, Harrison-Bernard LM, Dipp S, Yosipiv IV, and Meleg-Smith S. Bradykinin B2 null mice are prone to renal dysplasia: gene-environment interactions in kidney development. Physiol Genomics 3: 121-131, 2000.
17. El-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, and Vogelstein B. Definition of a consensus binding site for p53. Nat Genet 1: 45-49, 1992.
18. Farmer G, Friedlander P, Colgan J, Manley JL, and Prives C. Transcriptional repression by p53 involves molecular interactions distinct from those with the TATA box binding protein. Nucleic Acids Res 24: 4281-4288, 1996.
19. Fricke E, Keller G, Becker I, Rosivatz E, Schott C, Plaschke S, Rudelius M, Hermannstadter C, Busch R, Hofler H, Becker KF, and Luber B. Relationship between E-cadherin gene mutation and p53 gene mutation, p53 accumulation, Bcl-2 expression and Ki-67 staining in diffuse-type gastric carcinoma. Int J Cancer 104: 60-65, 2003.
20. Fuchs SY, Adler V, Pincus MR, and Ronai Z. MEKK1/JNK signaling stabilizes and activates p53. Proc Natl Acad Sci USA 95: 10541-10546, 1998.
21. Furnari B, Rhind N, and Russell P. Cdc25 mitotic inducer targeted by chk1 DNA damage checkpoint kinase. Science 277: 1495-1497, 1997.
22. Hajra KM, Ji X, and Fearon ER. Extinction of E-cadherin expression in breast cancer via a dominant repression pathway acting on proximal promoter elements. Oncogene 18: 7274-7279, 1999.
23. 2R(-/-)CRD mice. Am J Physiol Regul Integr Comp Physiol 285: R782-R790, 2003.
24. Jamal S and Schneider RJ. UV-induction of keratinocyte endothelin-1 downregulates E-cadherin in melanocytes and melanoma cells. J Clin Invest 110: 443-452, 2002.
25. Ji X, Woodard AS, Rimm DL, and Fearon ER. Transcriptional defects underlie loss of E-cadherin expression in breast cancer. Cell Growth Differ 8: 773-778, 1997.
26. Johnson RA, Ince TA, and Scotto KW. Transcriptional repression by p53 through direct binding to a novel DNA element. J Biol Chem 276: 27716-27720, 2001.
27. Ko LJ and Prives C. p53: Puzzle and paradigm. Genes Dev 10: 1054-1072, 1996.
28. Lagger G, Doetzlhofer A, Schuettengruber B, Haidweger E, Simboeck E, Tischler J, Chiocca S, Suske G, Rotheneder H, Wintersberger E, and Seiser C. The tumor suppressor p53 and histone deacetylase 1 are antagonistic regulators of the cyclin-dependent kinase inhibitor p21/WAF1/CIP1 gene. Mol Cell Biol 23: 2669-2679, 2003.
29. Larue L, Ohsugi M, Hirchenhain J, and Kemler R. E-cadherin null mutant embryos fail to form a trophectoderm epithelium. Proc Natl Acad Sci USA 91: 8263-8267, 1994.
30. Lee KC, Crowe AJ, and Barton MC. p53-Mediated repression of alpha-fetoprotein gene expression by specific DNA binding. Mol Cell Biol 19: 1279-1288, 1999.
31. Li JH, Zhu HJ, Huang XR, Lai KN, Johnson RJ, and Lan HY. Smad7 inhibits fibrotic effect of TGF-β on renal tubular epithelial cells by blocking Smad2 activation. J Am Soc Nephrol 13: 1464-1472, 2002.
32. Lilien J, Balsamo J, Arregui C, and Xu G. Turn-off, drop-out: functional state switching of cadherins. Dev Dyn 224: 18-29, 2002.
33. Mack DH, Vartikar J, Pipas JM, and Laimins LA. Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53. Nature 363: 281-283, 1993.
34. Marks J, Saifudeen Z, Dipp S, and El-Dahr SS. Two functionally divergent p53-responsive elements in the rat bradykinin B2 receptor promoter. J Biol Chem 278: 34158-34166, 2003.
35. Mishra N, Reilly CM, Brown DR, Ruiz P, and Gilkeson GS. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J Clin Invest 111: 539-552, 2003.
36. Murphy M, Ahn J, Walker KK, Hoffman WH, Evans RM, Levine AJ, and George DL. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev 13: 2490-2501, 1999.
37. Ogden SK, Lee KC, Wernke-Dollries K, Stratton SA, Aronow B, and Barton MC. p53 Targets chromatin structure alteration to repress α-fetoprotein gene expression. J Biol Chem 276: 42057-42062, 2001.
38. Oren M, Damalas A, Gottlieb T, Michael D, Taplick J, Leal JF, Maya R, Moas M, Seger R, Taya Y, and Ben-Ze'ev A. Regulation of p53: intricate loops and delicate balances. Biochem Pharmacol 64: 865-871, 2002.
39. Pause A, Lee S, Worrell RA, Chen DY, Burgess WH, Linehan WM, and Klausner RD. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci USA 94: 2156-2161, 1997.
40. Perez-Moreno M, Jamora C, and Fuchs E. Sticky business: orchestrating cellular signals at adherens junctions. Cell 112: 535-548, 2003.
41. Phelps DE and Dressier GR. Identification of novel Pax-2 binding sites by chromatin precipitation. J Biol Chem 271: 7978-7985, 1996.
42. Piscione TD and Rosenblum ND. The malformed kidney: disruption of glomerular and tubular development. Clin Genet 56: 341-356, 1999.
43. Pontoglio M, Barra J, Hadchouel M, Doyen A, Kress C, Bach JP, Babinet C, and Yaniv M. Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome. Cell 84: 575-585, 1996.
44. Riethmacher D, Brinkmann V, and Birchmeier C. A targeted mutation in the mouse E-cadherin gene results in defective preimplantation development. Proc Natl Acad Sci USA 92: 855-859, 1995.
45. Sablina AA, Chumakov PM, and Kopnin BP. Tumor suppressor p53 and its homologue p73α affect cell migration. J Biol Chem 278: 27362-27371, 2003.
46. Saifudeen Z, Dipp S, and El-Dahr SS. A role for p53 in terminal epithelial cell differentiation. J Clin Invest 109: 1021-1030, 2002.
47. Saifudeen Z, Du H, Dipp S, and El-Dahr SS. The bradykinin type 2 receptor is a target for p53-mediated transcriptional activation. J Biol Chem 275: 15557-15562, 2000.
48. Shieh SY, Ahn J, Tamai K, Taya Y, and Prives C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev 14: 289-300, 2000.
49. Shook D and Keller R. Mechanisms, mechanics and function of epithelial-mesenchymal transitions in early development. Mech Dev 120: 1351-1383, 2003.
50. Steinhusen U, Weiske J, Badock V, Tauber R, Bommert K, and Huber O. Cleavage and shedding of E-cadherin after induction of apoptosis. J Biol Chem 276: 4972-4980, 2001.
51. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 251: 1451-1455, 1991.
52. Timmermann S, Lehrmann H, Polesskaya A, and Harel-Bellan A. Histone acetylation and disease. Cell Mol Life Sci 58: 728-736, 2001.
53. Vestweber D, Kemler R, and Ekblom P. Cell-adhesion molecule uvomorulin during kidney development. Dev Biol 112: 213-221, 1985.
54. Vousden KH and Woude GF. The ins and outs of p53. Nat Cell Biol 2: E178-180, 2000.
55. Wheelock MJ and Johnson KR. Cadherins as modulators of cellular phenotype. Annu Rev Cell Dev Biol 19: 207-235, 2003.
56. Woods DF, Hough C, Peel D, Callaini G, and Bryant PJ. Dig protein is required for junction structure, cell polarity, and proliferation control in Drosophila epithelia. J Cell Biol 134: 1469-1482, 1996.
57. Yap AS and Kovacs EM. Direct cadherin-activated cell signaling: a view from the plasma membrane. J Cell Biol 160: 11-16, 2003.